Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary bioinformatics pipeline, Delve Decide.
Delve was founded by Charles Chiu, Joe DeRisi, and Michael Wilson.